Hainan Poly Pharm News

Prednisolone Pharmaceuticals: Announcement on the marketing approval of voriconazole injections from the Norwegian Medicines Agency

Apr 17 06:12 ET

Prednisolone Pharmaceuticals: Announcement on obtaining marketing approval for voriconazole injections from the Finnish National Drug Administration

Apr 8 05:48 ET

Prednisolone Pharmaceuticals: Announcement on obtaining marketing approval for voriconazole injections from the Swedish Medicines Agency

Apr 7 12:00 ET

Puri Pharmaceuticals: Announcement on Daptomycin for injections obtained marketing approval from the German Federal Institute for Drugs and Medical Devices (BfArM)

Apr 3 06:20 ET

Puli Pharmaceuticals: Announcement on the change of signed accountant

Apr 3 06:18 ET

Puli Pharmaceuticals: Announcement on the conversion of convertible corporate bonds to shares in the first quarter of 2024

Apr 1 06:36 ET

Puri Pharmaceuticals: Notice on submission of 8- (2-hydroxybenzamide) sodium caprylate (SNAC) pharmaceutical excipients to the U.S. DMF

Mar 14 06:32 ET

Puri Pharmaceuticals: Announcement on obtaining marketing approval for injectable pantoprazole sodium from the Department of Pharmacy of the Ministry of Health of Israel

Mar 5 02:58 ET

Puri Pharmaceuticals: Announcement on obtaining marketing approval for sodium nitrate injections in Germany

Feb 6 06:27 ET

Puli Pharmaceuticals: Announcement on 2024 Interest Payments on Convertible Corporate Bonds

Feb 2 05:43 ET

Puli Pharmaceuticals: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders

Jan 26 04:52 ET

Puli Pharmaceuticals: Legal Opinion of the 2024 First Extraordinary General Meeting of Shareholders

Jan 26 04:51 ET

Puli Pharmaceuticals: Prompt Announcement on Convening the First Extraordinary General Meeting of Shareholders in 2024

Jan 22 04:20 ET

Prednisolone Pharmaceuticals: Announcement on obtaining marketing approval for injectable voriconazole in Canada

Jan 11 02:46 ET

Puli Pharmaceuticals: Announcement on the launch of foreign exchange hedging business by the company and its wholly-owned subsidiaries

Jan 10 11:00 ET

Puli Pharmaceuticals: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2024

Jan 10 11:00 ET

Puli Pharmaceuticals: Announcement on the conversion of convertible corporate bonds to shares in the fourth quarter of 2023

Jan 2 04:10 ET

Puli Pharmaceuticals: Announcement on obtaining US drug clinical trial approval for PLAT001 for injection

Jan 1 18:52 ET

Pulley Pharmaceuticals: Announcement on the resignation of securities affairs representative

Dec 13, 2023 02:56 ET

Pulley Pharmaceuticals: Announcement on Pantoprazole Sodium for Injection Obtaining Marketing Approval from the Health Sciences Authority of Singapore

Dec 10, 2023 11:00 ET